University of Ioannina
Μελέτη της επίδρασης των αντιδιαβητικών παραγόντων στις συνάψεις των πυραμιδικών κυττάρων του ιππόκαμπου και του πιθανού τους ρόλου στην αντιμετώπιση της νόσου Alzheimer
Abstract
dc:descriptionAlzheimer’s disease (AD) is a progressive neurodegenerative disease of unknown etiology, estimated to cause dementia in more than 25 million people worldwide. Increased life expectancy and lifestyle changes are expected to increase the number of patients affected by AD during the following decades. The disease has a devastating impact on the patients and their families and caregivers, producing also a large burden for the society. AD is characterized by dementia that typically begins with subtle and poorly recognized failure of memory (often called mild cognitive impairment) and slowly becomes more severe and, eventually, incapacitating. Other disease findings include confusion, poor judgment, language disturbance, visual complaints, agitation, withdrawal, and hallucinations. The typical duration of the disease is eight to ten years. The diagnosis of AD is currently based on clinical signs of slowly progressive dementia, with neuroimaging findings of gross cerebral cortical atrophy, excluding other possible causes of dementia. Studies such as PET imaging and CSF or plasma concentrations of amyloid and tau are not yet routinely implicated in the everyday clinical practice, but they can increase the diagnostic accuracy in early stages of the disease and they are used in clinical trials. However, until today, there is no treatment that can stop or delay the degeneration caused by AD. Therefore, there is an urgent need to develop new pharmaceutical agents for the treatment of the disease and in this direction a great research effort is being made worldwide. Recent work, both clinical and experimental, indicates that neurodegenerative disorders display a coexisting metabolic dysfunction which may exacerbate neurological symptoms. Epidemiological studies and results obtained from animal models suggest a link between insulin resistance with aberrant cerebral insulin homeostasis and the appearance of AD pathology, such as Aβ plaques and Tau neurofibrillary tangles It stands to reason therefore that metabolic pathways may themselves contain promising therapeutic targets for neurodegenerative diseases. A variety of drugs that have been already tested or advanced in clinical trials, target metabolic factors such as insulin, a peptide that is secreted by pancreatic β cells and plays the most important role in regulating glucose metabolism in peripheral tissues. Recent research shows that insulin affects a variety of brain activities, such as enhancing the viability of neural synapses affecting glucose bioavailability. The proposed project aims to shed light on the cellular mechanisms of action of antidiabetic factors on the nervous system and enhance their properties for use against Alzheimer’s disease (AD).Oxidative stress has been implicated in several chronic pathological conditions, leading to cell death and injury. Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are both characterized by increased oxidative stress, inflammation, insulin resistance, and autophagy dysfunction. Given their common pathophysiological features, there is growing interest in exploring antidiabetic drugs as potential candidates for AD prevention and/or therapy. The results revealed that new generation antidiabetic agents (SGLT2i) exert a beneficial influence on the morphological alterations induced by hydrogen peroxide.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Katsenos, Andreas
- Κάτσενος, Ανδρέας
Subjects
dc:subject × 18- Νόσος Alzheimer
- Νευρώνες
- Δενδρίτες
- Δενδριτικές ακάνθες
- Σακχαρώδης διαβήτης τύπου 2 (ΣΔτ2)
- Αντιδιαβητικά φάρμακα
- Alzheimer's disease
- Neurons
- Dendrites
- Dendritic spines
- Type 2 diabetes mellitus
- Antidiabetic agents
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Νευροεπιστήμες
- Basic Medicine
- Medical and Health Sciences
- Neurosciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/56864